Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
03/2002
03/28/2002US20020037915 4-(4-(1- phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5-methylthiothiophene-2 -carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases
03/28/2002US20020037909 Enamine derivatives
03/28/2002US20020037900 Hydroxamic acid derivatives
03/28/2002US20020037889 Imidazolidin-2-one derivatives; inhibiting bone resorption, vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, arthritis, viral disease, cancer and metastatic tumor growth
03/28/2002US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/28/2002US20020037836 Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
03/28/2002US20020037574 Recombinant C-proteinase and processes, methods and uses thereof
03/28/2002US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections
03/28/2002US20020037523 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of nervous system, autoimmune, inflammation, glomerulonephritis and osteoporosis disorders
03/28/2002US20020037287 For diagnosis and therapy of myeloma and ovarian cancer
03/28/2002US20020037258 Amorphous bioactive particulate material consisting essentially of calcium, silicon and oxygen to alleviate sensitivity by causing the formation of calcium containing mineral within the dentinal tubules of sensitive teeth.
03/28/2002CA2433157A1 Cyclopentane derivatives as therapeutic agents
03/28/2002CA2424394A1 Growth factor complex comprising an insulin-like growth factor binding protein bound to vitronectin
03/28/2002CA2423106A1 Compounds and methods for modulation of estrogen receptors
03/28/2002CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
03/28/2002CA2423058A1 Polypeptide having phospholipase a2 activity
03/28/2002CA2423050A1 Pyrazine derivatives as modulators of tyrosine kinases
03/28/2002CA2422991A1 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
03/28/2002CA2422923A1 Pyridine derivatives with ikb-kinase (ikk-.beta.) inhibiting activity
03/28/2002CA2422911A1 New inhibitors of iapp fibril formation and uses thereof
03/28/2002CA2422686A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
03/28/2002CA2422215A1 B7-like molecules and uses thereof
03/28/2002CA2421485A1 Water soluble rapamycin esters
03/28/2002CA2421056A1 A polypeptide for use as a diagnostic marker for the presence of colon tumours
03/28/2002CA2420862A1 Protein phosphatases
03/27/2002EP1191099A1 Novel polypeptide and dna thereof
03/27/2002EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis
03/27/2002EP1190716A1 The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof
03/27/2002EP1190074A1 Recombinant anti-cd40 antibody and uses thereof
03/27/2002EP1190072A2 22012, a novel human carboxypeptidase
03/27/2002EP1190059A1 Sgip peptides
03/27/2002EP1190052A1 16405 receptor, a g-protein coupled receptor
03/27/2002EP1190051A2 Human transport proteins
03/27/2002EP1189946A1 ANTI-$g(a) v?$g(b)3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE
03/27/2002EP1189942A1 Somatostatin agonists
03/27/2002EP1189941A1 Neuromedin b and somatostatin receptor agonists
03/27/2002EP1189930A1 INHIBITORS OF THE INTEGRIN AlPHA V BETA 6
03/27/2002EP1189917A1 48 human secreted proteins
03/27/2002EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS
03/27/2002EP1189882A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
03/27/2002EP1189881A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
03/27/2002EP1189628A1 Combination of tumor necrosis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
03/27/2002EP1189612A1 Vla-4 inhibitor compounds
03/27/2002EP1189609A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics
03/27/2002EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers
03/27/2002EP1189583A1 Indole derivatives
03/27/2002EP0946562B1 PYRROLO[3,4-d]PYRIMIDINONE DERIVATIVES AND THEIR USE AS IMMUNOSUPPRESSANTS
03/27/2002CN1342202A Soluble receptor BR43X2 and methods for using them for therapy
03/27/2002CN1342196A Bifidobacterium in treatment of inflammatory disease
03/27/2002CN1342171A Process for production of multiple cross-linked hyaluronic acid derivatives
03/27/2002CN1342170A Process for cross-linking hyaluronic acid to polymers
03/27/2002CN1342167A Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction
03/27/2002CN1342166A GLP-1 analogues
03/27/2002CN1342162A Substituted 2-acyl-3-(heteroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compoistions and methods
03/27/2002CN1342157A Substituted pyrazoles ASP38 kinase inhibitors
03/27/2002CN1342150A Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors
03/27/2002CN1342149A Prostaglandin endoperoxide H synthase biosynthesis inhibitors
03/27/2002CN1342144A N-substituted benzoyl indoles as estrogenic agents
03/27/2002CN1342083A Uses of 1-amino-3-(N,N-dimethylamino)propylidene-1,1-bisphosphonic acid
03/27/2002CN1342077A Inhibition of formation of vascular hyperpermeability
03/27/2002CN1342073A Antioxidant compositions and methods for companion animals
03/27/2002CN1341593A Proteinase inhibitor
03/27/2002CN1341592A Proteinase inhibitor
03/27/2002CN1341590A Proteinase inhibitor
03/27/2002CN1341429A Helth-care food with functions of protecting liver and resisting osteoporosis
03/26/2002US6362227 Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen
03/26/2002US6362213 Antiinflammatory agents; central nervous system disorders
03/26/2002US6362195 Inhibitor of nitric oxide synthase; central nervous system disorders
03/26/2002US6362193 Antiinflammatory agents
03/26/2002US6362190 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, n'-((1-(aminoiminomethyl)4-piperidinyl) methyl)-n-(3,3-diphenylpropionyl)-l-proline amide
03/26/2002US6362176 Compositions, methods and kits for treating rheumatoid arthritis
03/26/2002US6362163 Administering polypeptide
03/26/2002US6361768 Hydrophilic ampholytic polymer
03/26/2002CA2137551C A novel endothelial cell molecule mediating lymphocyte binding in man
03/21/2002WO2002022871A2 Polymorphic bone morphogenetic protein 2
03/21/2002WO2002022851A2 Novel tumor-associated marker
03/21/2002WO2002022805A2 Modulation of il-2- and il-15-mediated t cell responses
03/21/2002WO2002022682A1 Interferon-alpha induced gene
03/21/2002WO2002022680A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)
03/21/2002WO2002022630A1 Purine derivatives
03/21/2002WO2002022621A2 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS
03/21/2002WO2002022620A2 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists
03/21/2002WO2002022616A2 Alpha v integrin receptor antagonists
03/21/2002WO2002022615A1 Alpha v integrin receptor antagonists
03/21/2002WO2002022611A2 Caspase inhibitors and uses thereof
03/21/2002WO2002022610A1 Isoxazoles and their use as inhibitors of erk
03/21/2002WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022602A2 Triazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022599A2 Chemokine receptor binding heterocyclic compounds
03/21/2002WO2002022585A1 Tetrahydroquinoline compounds
03/21/2002WO2002022574A1 Tricyclic heterocyclic compound, process for producing the same, and use thereof
03/21/2002WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
03/21/2002WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
03/21/2002WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
1 ... 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 ... 820